WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Stop TB Communicable Diseases
Treat 3 Million by 2005
WHO/HIV/2005.02
African Region
A Snapshot of European Collection Schemes
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
Рекомендации ВОЗ по оказанию дородовой помощи для формирования положительного опыта беременности
Regional Tuberculosis Program, Pan American Health Organization (PAHO/WHO)
SADC Communicable Disease Project
Component 5: Scaling-up Child and Adolescent HIV, TB and Malaria Continuum of Care and Support
DRAFT POST REGIONAL CONSENSUS AND VALIDATION MEETING Oct 2012